Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium

Autor: Francesco Rossi, Donato Cappetta, Agostino Miccichè, Silvio Naviglio, Annalisa Capuano, Loreta Pia Ciuffreda, Raffaele Coppini, Lucia Altucci, Cristina Scavone, Chiara Palandri, Liberato Berrino, Anna Cozzolino, Filippo Crea, Eleonora Cianflone, Domenico D'Amario, Marcello Rota, Konrad Urbanek, Antonella De Angelis, Carmela Dell'Aversana, Lorenzo Santini

Publikováno v: Pharmacological research (Online) 157 (2020). doi:10.1016/j.phrs.2020.104781
info:cnr-pdr/source/autori:Cappetta D.; De Angelis A.; Ciuffreda L.P.; Coppini R.; Cozzolino A.; Micciche A.; Dell'Aversana C.; D'Amario D.; Cianflone E.; Scavone C.; Santini L.; Palandri C.; Naviglio S.; Crea F.; Rota M.; Altucci L.; Rossi F.; Capuano A.; Urbanek K.; Berrino L./titolo:Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium/doi:10.1016%2Fj.phrs.2020.104781/rivista:Pharmacological research (Online)/anno:2020/pagina_da:/pagina_a:/intervallo_pagine:/volume:157

The results of trials with sodium-glucose cotransporter 2 (SGLT2) inhibitors raised the possibility that this class of drugs provides cardiovascular benefits independently from their anti-diabetic effects, although the mechanisms are unknown. Therefo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76378511cb50a44325d56a53101d8cad
http://hdl.handle.net/10807/166769